September 11, 2008
Seigo Izumo, MD Joins Gilead as Senior Vice President, Cardiovascular Therapeutics
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sept. 11, 2008--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Seigo Izumo, MD has joined the company as Senior Vice President, Cardiovascular Therapeutics. Dr. Izumo will report to Norbert Bischofberger, PhD, Gilead's Executive Vice President, Research and Development and Chief Scientific Officer. Dr. Izumo will oversee Gilead's growing cardiovascular business unit and will serve as a member of Gilead's executive committee.
"Seigo's depth of knowledge in cardiovascular science and medicine will be of great value to our team and ultimately to the patients we serve," said Dr. Bischofberger. "His experience in both laboratory science and clinical research, together with his leadership capabilities, will ensure continued advancement of programs to address unmet needs in cardiovascular medicine."
Dr. Izumo most recently served as Vice President & Global Head of Cardiovascular Research at Novartis Institutes for BioMedical Research. Prior to joining Novartis in July 2003, he served as Professor of Medicine at Harvard Medical School in Boston and at Harvard-MIT Division of Health Sciences and Technology. In addition to his academic position at Harvard, Dr. Izumo was Director of Cardiovascular Research and Physician, Department of Medicine, Beth Israel Deaconess Medical Center, Boston and Director of the CardioGenomics Program, a National, Heart Lung and Blood Institute-sponsored initiative. Previously, he was Chief of the Cardiology Division and Professor of Internal Medicine and Biological Chemistry, University of Michigan Medical School in Ann Arbor. Dr. Izumo received his undergraduate and medical degrees from the University of Tokyo.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
CONTACT: Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)
SOURCE: Gilead Sciences, Inc.